Sign inJoin waitlistJoin the waitlist

Manali Kamdar

Clinical Director of Lymphoma Services · University of Colorado School of Medicine

Credentials: · · · ·

History

Lymphoma Services · University of Colorado School of Medicine
Present
Lymphoma Program · University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present

Pitt County Memorial Hospital/East Carolina University Program
Stanford University Program
Pitt County Memorial Hospital/East Carolina University Program
KJ Somaiya Medical College
2005

Research

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or…
The Lancet · 2022 · First of 22 authors · Corresponding · 698 citations
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology · 2020 · 647 citations
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3…
The Lancet · 2020 · 554 citations

JA
Jeremy Abramson
22 papers
BK
Brad Kahl
19 papers
Brian Hill
18 papers
Matthew Lunning
18 papers
Reem Karmali
18 papers
Brad Haverkos
17 papers
Veronika Bachanova
17 papers
Mazyar Shadman
16 papers
Ajay Major
13 papers · 9 as a resident
Deborah Stephens
12 papers
Craig Portell
11 papers
Narendranath Epperla
11 papers

Clinical trials

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Principal investigator · Recruiting · Phase 1
University of Colorado, Denver
2021–2027
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
Principal investigator · Completed · Phase 2
University of Colorado, Denver
2020–2022
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Principal investigator · Completed · Phase 1
University of Colorado, Denver
2020–2023
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032